Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
Clinicians now have a new tool to help diagnose symptomatic patients with Herpes Simplex Viruses (HSV1 and HSV2) — one of the most common sexually transmitted infections in the world. BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today that it received U.S…
|
2
Dec |
Southampton Scientists To Develop New Rapid Test In Fight Against Sexually Transmitted InfectionsCategory: Sexual Health / STDs | Leave a Comment |
Scientists from the University of Southampton have secured funding to develop an ultra-rapid sexually transmitted infection (STI) detection system for clinics that can detect STIs in under 15 minutes…
|
5
Oct |
Gen-Probe Files US Regulatory Application For Molecular Test To Detect Common Sexually Transmitted Disease Trichomonas VaginalisCategory: Sexual Health / STDs | Leave a Comment |
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system…
|
18
Aug |
Chlamydia Detection Device Gets Funding InjectionCategory: Sexual Health / STDs | Leave a Comment |
A Tyneside company has been awarded government funding to develop unique mobile devices which could dramatically improve the detection of sexually transmitted diseases (STDs) like Chlamydia…
|
28
Jul |
DIATHERIX Laboratories Launches STD And HSV Test PanelCategory: Sexual Health / STDs | Leave a Comment |
DIATHERIX Laboratories, adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods…
|
3
Jul |
Gen-Probe Receives European CE Mark For Molecular Test To Detect Common Sexually Transmitted Disease Trichomonas VaginalisCategory: Sexual Health / STDs | Leave a Comment |
Gen-Probe Incorporated (Nasdaq: GPRO) announced that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease…
|
29
Jun |
Abbott Receives FDA Clearance For Molecular Diagnostic Test For Detection Of Chlamydia And Gonorrhea InfectionsCategory: Sexual Health / STDs | Leave a Comment |
Abbott (NYSE: ABT) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation’s most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden…
|
26
Mar |
Study Finds Women Prefer Home Testing For Chlamydia, GonorrheaCategory: Sexual Health / STDs | Leave a Comment |
About 75% of women preferred to complete a chlamydia or gonorrhea test at home and mail the sample for analysis, compared with 16% who preferred testing at a no-cost clinic and 8% who wanted to visit their own health care provider, according to a study published in the April issue of Obstetrics & Gynecology, MedPage Today reports…
|
24
Oct |
Need For Accurate Testing For Early Syphilis InfectionCategory: Sexual Health / STDs | Leave a Comment |
Although syphilis is one of the oldest known diseases, most health professionals do not have access to the tests necessary to reliably diagnose it in its earliest and most infectious stage. A recent survey of infectious diseases specialists regarding the diagnosis and treatment of syphilis appears in the November 15, 2009 issue of Clinical Infectious Diseases, now available online.
|
29
Jul |
Rapid, Pain-Free Test For Men Offered By New Chlamydia TestCategory: Sexual Health / STDs | Leave a Comment |
A new urine test developed with funding from the Wellcome Trust will allow doctors to diagnose Chlamydia infection in men within the hour, improving the ability to successfully treat the infection on the spot and prevent re-transmission. Chlamydia, caused by the bacterium Chlamydia trachomatis, is the most common sexually-transmitted bacterial infection in the UK, particularly amongst sexually active men and women aged 16-24 years.